These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24957823)

  • 1. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Dooley KE; Luetkemeyer AF; Park JG; Allen R; Cramer Y; Murray S; Sutherland D; Aweeka F; Koletar SL; Marzan F; Bao J; Savic R; Haas DW;
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5245-52. PubMed ID: 24957823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Mallikaarjun S; Wells C; Petersen C; Paccaly A; Shoaf SE; Patil S; Geiter L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5976-85. PubMed ID: 27458223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
    Francis J; Mngqibisa R; McIlleron H; Kendall MA; Wu X; Dooley KE; Firnhaber C; Godfrey C; Cohn SE; Denti P;
    Clin Pharmacol Ther; 2021 Oct; 110(4):1057-1065. PubMed ID: 34151439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.
    Ng J; Chiu YL; Awni W; Bernstein B; Causemaker SJ; Klein CE
    J Clin Pharmacol; 2012 Aug; 52(8):1248-54. PubMed ID: 21719718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
    Boulanger C; Rolla V; Al-Shaer MH; Peloquin C
    Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
    Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
    Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
    la Porte CJ; Colbers EP; Bertz R; Voncken DS; Wikstrom K; Boeree MJ; Koopmans PP; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2004 May; 48(5):1553-60. PubMed ID: 15105105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
    PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
    Dooley KE; Park JG; Swindells S; Allen R; Haas DW; Cramer Y; Aweeka F; Wiggins I; Gupta A; Lizak P; Qasba S; van Heeswijk R; Flexner C;
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):455-62. PubMed ID: 22126739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
    Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
    Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
    Rabie H; Rawizza H; Zuidewind P; Winckler J; Zar H; Van Rie A; Wiesner L; McIlleron H
    J Antimicrob Chemother; 2019 Aug; 74(8):2347-2351. PubMed ID: 31081020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.